Name: Cougar Biotechnology Inc. - BioCentury Company Profiles - BCIQ
Creator: Biocentury

signInButton

SIGN IN

Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Please note, you are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry. Request a trial to unlock the full value of BCIQ.

REQUEST A FREE TRIAL

AcquiredOrMerged

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.

If you believe a company has been archived in error, please contact us at 

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.\nIf you believe a company has been archived in error, please contact us at \nsupport@biocentury.com\n.

Cat-H(AcquiredorMerged)

Historical deals and financings can be found by searching the organization's name in the BCIQ <DEALS> and <FINANCING> Modules.

Default (Company Type Blank)

CategoryHDefault (Company Type Blank)

NonBioPharma

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.

Cat-H(NonBioPharma)

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.\n

Cougar Biotechnology Inc.

Public equity report: Symbiotic Capital launches with $600M credit fund

Biopharma companies are still undervaluing external innovation

J&J appeals district court decision invalidating Zytiga patent

FDA expands label for Zytiga

PTAB invalidates Zytiga patent

PTAB invalidates Zytiga patent

CHMP recommends label expansion for J&J prostate cancer drug Zytiga

J&J's Zytiga meets in Phase II/III STAMPEDE trial for hormone-naïve prostate cancer

J&J's Zytiga meets in Phase III LATITUDE trial for hormone-naïve prostate cancer

J&J sales and marketing update